Diabetic Retinopathy
Indian Journal of Endocrinology and Metabolism · 2022-03 · 26 (2) · 111-118
DOI: 10.4103/ijem.ijem_480_21 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Indian Journal of Endocrinology and Metabolism, 2022-03. Verfasst von Bassirou A M Mounirou und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Endocrinology and Metabolic Diseases, First Affiliated Hospital of Jiamusi University, Jiamusi, China. Die Arbeit wurde bisher 61-mal zitiert (Crossref) und nennt 103 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Diabetic retinopathy (DR), substantially impacts the quality of life of diabetic patients, it remains, in developed countries, the leading cause of vision loss in working-age adults (20–65 years). Currently, about 90 million diabetics suffer from DR. DR is a silent complication that in its early stages is asymptomatic. However, over time, chronic hyperglycemia can lead to sensitive retinal damage, leading to fluid accumulation and retinal haemorrhage (HM), resulting in cloudy or blurred vision. It can, therefore, lead to severe visual impairment or even blindness if left untreated. It can be classified into nonproliferative diabetic retinopathy (NPDR) and proliferative diabetic retinopathy (PDR). NPDR is featured with intraretinal microvasculature changes and can be further divided into mild, moderate, and severe stages that may associate with diabetic macular oedema (DME). PDR involves the formation and growth of new blood vessels (retinal neovascularisation) under low oxygen conditions. Early identification and treatment are key priorities for reducing the morbidity of diabetic eye disease. In the early stages of DR, a tight control of glycemia, blood pressure, plasma lipids, and regular monitoring can help prevent its progression to more advanced stages. In advanced stages, the main treatments of DR include intraocular injections of anti-vascular endothelial growth factor (VEGF) antibodies, laser treatments, and vitrectomy. The aim of this review is to provide a comprehensive overview of the published literature pertaining to the latest progress in the treatment of DR.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Endocrinology and Metabolic Diseases, First Affiliated Hospital of Jiamusi University, Jiamusi, China.
- Department of Ophthalmology, Lamorde National Hospital, Niamey, Niger.
- Department of Ophthalmology, National Hospital of Niamey, Niamey, Niger.
- Department of Endocrinology and Metabolic Diseases, General Reference Hospital of Niamey, Niger.
Zitieren
APA
Mounirou, B. A. M., Adam, N. D., Yakoura, A. K. H., Aminou, M. S. M., Liu, Y. T., & Tan, L. Y. (2022). Diabetic Retinopathy. Indian Journal of Endocrinology and Metabolism, 26(2), 111-118. https://doi.org/10.4103/ijem.ijem_480_21
Vancouver
Mounirou BAM, Adam ND, Yakoura AKH, Aminou MSM, Liu YT, Tan LY. Diabetic Retinopathy. Indian Journal of Endocrinology and Metabolism. 2022;26(2):111-118. doi:10.4103/ijem.ijem_480_21
BibTeX
@article{Mounirou2022,
author = {Mounirou, Bassirou A M and Adam, Nouhou D and Yakoura, Abba K H and Aminou, Mahamane S M and Liu, Yu T and Tan, Li Y},
title = {Diabetic Retinopathy},
journal = {Indian Journal of Endocrinology and Metabolism},
year = {2022},
volume = {26},
number = {2},
pages = {111--118},
doi = {10.4103/ijem.ijem_480_21}
}
EUVIMED